

University of Groningen

## Impact of hidradenitis suppurativa on work productivity and associated risk factors

van Straalen, Kelsey R.; Prens, Lisette M.; Hylkema, Tjerk H.; Janse, Ineke C.; Dickinson, Janine; Houwing, Ronald; van der Zee, Hessel H.; Brouwer, Sandra; Prens, Errol P.; Horvath, Barbara

*Published in:*  
Journal of the American Academy of Dermatology

*DOI:*  
[10.1016/j.jaad.2020.07.115](https://doi.org/10.1016/j.jaad.2020.07.115)

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*  
Publisher's PDF, also known as Version of record

*Publication date:*  
2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

van Straalen, K. R., Prens, L. M., Hylkema, T. H., Janse, I. C., Dickinson, J., Houwing, R., van der Zee, H. H., Brouwer, S., Prens, E. P., & Horvath, B. (2021). Impact of hidradenitis suppurativa on work productivity and associated risk factors. *Journal of the American Academy of Dermatology*, 84(5), 1401-1405. <https://doi.org/10.1016/j.jaad.2020.07.115>

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

aggressively with the goal of thwarting progression and eventual debilitation. Taken together, patients with HS with moderate to severe disease and, potentially, those with milder HS, may be undertreated. Undertreatment is likely to result in additional morbidities such as symptoms reflecting progression in course, including pain, drainage, odor, and disease flares.<sup>2</sup>

In a prior study, having established dermatology care resulted in the greatest likelihood of initiating and escalating treatment for HS.<sup>3</sup> This observation is likely related to the expertise of dermatologists in evaluating and managing patients with HS, as well to familiarity with use of biologics. However, use of dermatology care by patients with HS in this analysis was low, as it was in a 2017 study in which only 22% of patients with HS were observed to have an established dermatologist.<sup>4</sup> Moreover, a third of HS patients having a dermatologist report difficulty accessing their doctor.<sup>2</sup> Accordingly, there is likely opportunity to improve morbidity in HS by augmenting awareness of the role of dermatologists, by improving access, and by our timely use of more effective interventions.

Whether men or younger patients with HS have greater disease severity or are more willing to accept biologic treatment warrants further study. Our inability to capture patients who did not seek care in health systems included in the database is a limitation.

In conclusion, we observed a very low percentage of patients with HS receiving prescription for Ada/Ifx, including those with a dermatology relationship. Biologic therapy may not be appropriate for all patients with moderate to severe HS. Nonetheless, our results suggest an opportunity to improve symptoms and disease course in HS by expanding the appropriate use of Ada/Ifx, consistent with efficacy data and treatment guidelines.

Lauren A. V. Orenstein, MD,<sup>a</sup> Shari Wright, BS,<sup>b</sup>  
Andrew Strunk, MA,<sup>b</sup> and Amit Garg, MD<sup>b</sup>

From the Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia<sup>a</sup>; and Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.<sup>b</sup>

Funding sources: Lauren A.V. Orenstein's participation was supported in part by the Building Interdisciplinary Research Careers in Women's Health of the National Institutes of Health under award number K12D085850. The funding agency did not have any input in the study

design, data collection, data analysis, manuscript publication, or publication decisions. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Disclosure: Lauren A.V. Orenstein is an investigator for Chemocentryx. Amit Garg is an advisor for AbbVie, Amgen, Boehringer Ingelheim, Incyte, Janssen, Novartis, Pfizer, UCB, and Viela Bio and receives research grants from AbbVie and the National Psoriasis Foundation. Authors Wright and Strunk have no conflicts of interest to declare.

IRB approval status: Reviewed and approved by the human subjects committee of the Feinstein Institutes for Medical Research at Northwell Health.

Reprints not available from the authors.

Correspondence to: Amit Garg, MD, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 1991 Marcus Avenue, Suite 300, New Hyde Park, NY 11042

E-mail: [amgarg@northwell.edu](mailto:amgarg@northwell.edu)

#### REFERENCES

1. Strunk A, Midura M, Papagermanos V, Alloo A, Garg A. Validation of a case-finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database. *Dermatology*. 2017;233(1):53-57.
2. Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global VOICE project. *J Am Acad Dermatol*. 2019;82(2):366-376.
3. Garg A, Besen J, Legler A, Lam CS. Factors associated with point-of-care treatment decisions for hidradenitis suppurativa. *JAMA Dermatol*. 2016;152(5):553-557.
4. Garg A, Lavian J, Strunk A. Low utilization of the dermatology ambulatory encounter among patients with hidradenitis suppurativa: a population-based retrospective cohort analysis in the USA. *Dermatology*. 2018;233(5):396-398.

<https://doi.org/10.1016/j.jaad.2020.07.108>

#### Impact of hidradenitis suppurativa on work productivity and associated risk factors



To the Editor: Matusiak et al<sup>1</sup> showed that hidradenitis suppurativa (HS) caused absenteeism in 58.1%

**Table I.** Patient characteristics\*

	Overall <sup>†</sup> (N = 843)	Workers <sup>‡</sup> (n = 523)	Nonworkers <sup>‡</sup> (n = 320)	P value <sup>§</sup>
Patient characteristics				
Sex				
Female, n (%)	604 (71.6)	373 (61.8)	231 (38.2)	.79
Age, y, mean (SD)	38.0 (12.2)	37.3 (11.3)	39.0 (13.6)	.06
Age at onset, y, median (IQR)	20.0 (15.0-27.0)	20.0 (15.0-27.0)	19.0 (15.0-28.0)	.62
Missing, n	27	15	12	
Disease duration, y, median (IQR)	12.5 (6.0-22.0)	12.8 (6.5-21.0)	12.1 (5.1-25.3)	.51
Missing, n	27	15	12	
BMI, kg/m <sup>2</sup> , mean (SD)	28.7 (6.3)	28.5 (6.1)	29.1 (6.5)	.23
Current or ex-smoker, n (%)	643 (76.3)	390 (60.7)	253 (39.3)	.16
Positive family history	121 (23.8)	92 (76.0)	29 (24.0)	<.001
Unknown, n (%)	115 (22.6)	64 (55.7)	51 (44.3)	
Missing, n	335	195	180	
Education level, n (%)				
Low	148 (17.6)	65 (43.9)	83 (56.1)	
Medium	483 (57.3)	300 (62.1)	183 (37.9)	
High	212 (25.1)	158 (74.5)	54 (25.5)	<.0001
Comorbidities				
Rheumatoid arthritis, n (%)	25 (4.2)	12 (48.0)	13 (52.0)	.08
Missing, n	241	134	107	
Fibromyalgia, n (%)	9 (1.5)	2 (22.2)	7 (77.8)	.008
Missing, n	242	138	104	
Spondyloarthritis, n (%)	5 (0.9)	5 (100.0)	0 (0.0)	NP
Missing, n	286	139	147	
Crohn's disease, n (%)	35 (5.8)	19 (54.3)	16 (45.7)	.18
Missing, n	240	133	107	
Ulcerative colitis, n (%)	5 (0.8)	3 (60.0)	2 (40.0)	.82
Missing, n	247	137	110	
Psoriasis, n (%)	37 (6.2)	20 (54.1)	17 (45.9)	.17
Missing, n	247	139	108	
Previous depression, n (%)	119 (19.3)	53 (44.5)	66 (55.5)	<.0001
Missing, n	226	134	92	
Physician scores				
Hurley classification, n (%)				
Stage I	390 (46.3)	242 (62.1)	148 (37.9)	.18
Stage II	368 (43.7)	224 (60.9)	144 (39.1)	
Stage III	85 (10.0)	57 (67.1)	28 (32.9)	
Refined Hurley, n (%)				
Mild (IA, IIA)	363 (43.1)	227 (61.2)	137 (37.7)	
Moderate (IB, IIB)	195 (23.1)	132 (77.4)	63 (32.3)	
Severe (IC, IIC, III)	285 (33.8)	164 (57.5)	120 (42.1)	.003
IHS4, mean (SD)	9.4 (15.3)	9.5 (17.0)	9.1 (11.9)	.66
Mild, n (%)	366 (43.4)	223 (60.9)	144 (39.3)	.53
Moderate, n (%)	232 (27.5)	151 (65.1)	81 (34.9)	
Severe, n (%)	245 (29.1)	150 (61.2)	96 (39.2)	
Presence of draining sinus tracts, n (%)	349 (41.4)	217 (62.2)	132 (37.8)	.94
Affected locations, n (%)				
Axillae	295 (35.0)	192 (65.1)	102 (34.6)	.15
Groin/buttocks	510 (60.5)	298 (58.4)	212 (41.6)	.008
Patient-reported outcome measures				
DLQI, mean (SD)	11.5 (7.6)	10.8 (7.3)	12.6 (8.0)	<.001
EQ-5D-5 Level, median (IQR)	0.75 (0.62-0.84)	0.77 (0.66-0.87)	0.69 (0.49-0.81)	<.001
Missing, n	278	156	122	
EQ-5D VAS, median (IQR)	70.0 (51.0-80.0)	70.0 (60.0-80.0)	60.0 (45.0-75.0)	<.001
Missing, n	263	147	116	

Continued

**Table I.** Cont'd

	Overall <sup>†</sup> (N = 843)	Workers <sup>‡</sup> (n = 523)	Nonworkers <sup>‡</sup> (n = 320)	P value <sup>§</sup>
NRS Pain, mean (SD)	5.3 (3.0)	5.2 (2.9)	5.6 (3.0)	<b>.04</b>
NRS Pruritus, mean (SD)	4.1 (3.0)	3.8 (2.9)	4.6 (3.1)	<b>&lt;.001</b>
NRS Severity, mean (SD)	6.0 (2.8)	5.8 (2.7)	6.2 (2.8)	.09
HADS Depression, median (IQR)	5.0 (2.0-9.0)	3.0 (1.0-6.0)	8.0 (3.0-11.0)	<b>&lt;.001</b>
Missing, n	481	307	174	
HADS Anxiety, median (IQR)	6.0 (3.0-10.0)	5.0 (3.0-8.0)	8.0 (4.0-12.0)	<b>&lt;.001</b>
Missing, n	481	307	174	

BMI, Body mass index; DLQI, Dermatology Life Quality Index; HADS, Hospital Anxiety and Depression Survey; EQ-5D, EuroQol-5 Dimensions; IHS4, International Hidradenitis Suppurativa Severity Score System; IQR, interquartile range; NRS, numeric rating scale; SD, standard deviation; VAS, visual analogue scale.

Bold data indicates statistical significance.

\*Numbers and percentages may not add up to 100% because of rounding of pooled data.

<sup>†</sup>Percentages in this column are reported as percentages of the overall number of patients.

<sup>‡</sup>Percentages in these columns are presented as percentages of the variable on that row.

<sup>§</sup>P-value calculated between workers and nonworkers.

of patients. However, work impairment due to HS is not limited to absenteeism but could also lead to presenteeism (reduced productivity while at work) and at-work productivity loss (absenteeism plus presenteeism). Knowledge of which HS-related factors are associated with absenteeism, presenteeism, and at-work productivity loss is essential. Therefore, we aimed to assess differences between working and nonworking patients with HS; quantify absenteeism, presenteeism, and at-work productivity loss caused by HS; and identify associated risk factors.

All newly referred consecutive patients participating in the HiCARE (METc 2018/110), HiSure (METc 2015/074), and HiScreen (MEC-2016-246) registries between April 2015 and July 2019 were included. Patient characteristics, disease severity, patient-reported outcomes, and comorbidities were collected, and the Work Productivity and Activity Impairment questionnaire, specific health problem version, was used to assess the influence of HS on absenteeism, presenteeism, and at-work productivity loss. See the Supplemental Methods (available via Mendeley at <https://doi.org/10.17632/6nmk748p89.1>) for details on the between-group analyses, multiple imputations, and regression analyses.

Overall, 62.0% (523/843) of patients had work at the time of inclusion. The presence of inguinal/gluteal HS, increased HS severity, higher pain scores, the presence of fibromyalgia, and higher depression and anxiety scores were significantly more common in nonworkers (Table I). Twenty-six percent of working patients reported actual work time missed, with a median absenteeism of 0% (95% confidence interval [CI], 0.0-5.3). Workers reported a median presenteeism due to HS of 20% (95% CI, 0.0-50.0) and a median at-work productivity loss of 20.0%

(95% CI, 0.0-69.0). Results from the univariate regressions analyses are presented in Supplemental Table I (available via Mendeley at <https://doi.org/10.17632/6nmk748p89.1>). Pain, Dermatology Life Quality Index, and EuroQol-5 Dimensions scores were significantly associated with presenteeism and at-work productivity loss in the multivariate regression models (Table II).

The level of absenteeism found in our study seems to be slightly lower than that found in a Danish study and substantially lower than that found in a Canadian study: 7.0% ± 21.2% and 14.5% ± 27.0%, respectively.<sup>2,3</sup> One explanation could be the larger proportion of nonworking patients in our study. In The Netherlands (and Denmark), adequate unemployment benefits are provided, which might lead to a higher percentage of nonworking patients and potentially lower levels of absenteeism among those still at work. This highlights that unemployment and work productivity data among patients with HS should be interpreted and extrapolated with caution because the results are highly influenced by the work climate and access to unemployment benefits in the study country.

Nonetheless, the factors associated with nonwork and at-work productivity loss in our study are modifiable through medical and/or surgical treatment, which could have a favorable effect on work status and productivity. However, this cross-sectional study does not allow for the assessment of causality in the found associations.

Overall, this study shows that several potentially modifiable factors such as inguinal/gluteal involvement, more severe disease, and higher depression and anxiety scores are more common among nonworkers. Additionally, among working patients, pain

**Table II.** Multivariate\* linear and logistic regression analyses

Assessment	Absenteeism			Presenteeism			At-work productivity loss			
	n	B	OR (95% CI)	P value	n	B (95% CI)	P value	n	B (95% CI)	P value
IHS4					305	0.320 (-0.001 to 0.641)		305	0.320 (-0.001 to 0.641)	.051
DLQI score	316	0.076	1.079 (1.024 to 1.137)	.004	302	1.720 (1.235 to 2.205)	<.001	305	1.904 (1.335 to 2.473)	<.001
EQ-5D index score	316	-1.703	0.182 (0.030 to 1.111)	.065	302	-23.147 (-40.483 to -5.811)	.009	305	-29.222 (-49.592 to -8.853)	.005
NRS Pain	316	0.146	1.157 (1.022 to 1.311)	.021	302	2.446 (1.464 to 3.428)	<.001	305	2.373 (1.189 to 3.556)	<.001

CI, Confidence interval; DLQI, Dermatology Life Quality Index; EQ-5D, EuroQol-5 Dimensions; IHS4, International Hidradenitis Suppurativa Severity Score System; NRS, numeric rating scale; OR, odds ratio.

\*All multivariate models were corrected for sex, age, BMI, smoking, educational level, and smoking status.

and quality of life are associated with at-work productivity loss. This indicates the need for adequate treatment and pain management to limit work absence and reduce at-work productivity loss among patients with HS.

*Kelsey R. van Straalen, MD,<sup>a,b</sup> Lisette M. Prens, MD,<sup>c</sup> Tjerk H. Hylkema, MD, PhD,<sup>d</sup> Ineke C. Janse, MD, PhD,<sup>e</sup> Janine Dickinson, MD, PhD,<sup>f</sup> Ronald Houwing, MD, PhD,<sup>g</sup> Hessel H. van der Zee, MD, PhD,<sup>a,b</sup> Sandra Brouwer, MD, PhD,<sup>d</sup> Errol P. Prens, MD, PhD,<sup>a,b</sup> and Barbara Horváth, MD, PhD<sup>c</sup>*

*From the Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands<sup>a</sup>; European Reference Network Skin, Paris, France<sup>b</sup>; Department of Dermatology, University Medical Center Groningen, Groningen, The Netherlands<sup>c</sup>; Department of Health Sciences, Community and Occupational Medicine and University Medical Center Groningen, University of Groningen, Groningen, The Netherlands<sup>d</sup>; Department of Dermatology, Meander Medical Center, Amersfoort, The Netherlands<sup>e</sup>; Department of Dermatology, Nij Smellinghe Hospital, Drachten, The Netherlands<sup>f</sup>; and Department of Dermatology, Deventer Hospital, Deventer, The Netherlands.<sup>g</sup>*

*Funding sources: The HiCARE/HiSURE and HiScreen registries are co-funded by AbbVie Netherlands. The cofunder had no role in the design or conduct of the study, the interpretation of the data, or the decision to submit the manuscript for publication.*

*Conflicts of interest: None disclosed.*

*IRB approval status: The HiScreen Registry was approved by the IRB of the Erasmus University Medical Centre (MEC-2016-246); HiCARE (METc 2018/110) and HiSure (METc 2015/074) were approved by the IRB of the University Medical Center Groningen.*

*Drs van Straalen and L. Prens contributed equally to this article.*

*Correspondence to: Barbara Horváth, MD, PhD, Department of Dermatology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands*

*E-mail: b.horvath@umcg.nl*

**REFERENCES**

1. Matusiak Ł, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. *J Am Acad Dermatol.* 2010;62(4):706-708.

2. Yao Y, Jørgensen AR, Thomsen SF. Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. *Int J Dermatol.* 2020;59(3):333-340.
3. Sandhu VK, Shah M, Piguet V, Alavi A. The impact of Hidradenitis suppurativa on work productivity and activity impairment. *Br J Dermatol.* 2020;182(5):1288-1290.

<https://doi.org/10.1016/j.jaad.2020.07.115>

### Serum cytokine levels in patients with hidradenitis suppurativa vary with race




*To the Editor:* Hidradenitis suppurativa (HS) is a chronic condition characterized by painful nodules and abscesses in intertriginous areas that can lead to disfigurement. The presumed immunopathogenesis of HS involves an exaggerated response to ruptured follicles. Aberrant cytokine expression has been demonstrated in the serum of patients with HS, specifically, increased serum tumor necrosis factor (TNF)- $\alpha$ ,<sup>1</sup> interleukin (IL)-17,<sup>2</sup> and IL-1 $\beta$ .<sup>3</sup> Although biologics targeting TNF- $\alpha$  and IL-1 have shown success, the quest for additional treatment options remains ongoing.

In this institutional review board–approved study, we aimed to characterize serum cytokine profiles in HS. Adults with HS and healthy age-, sex-, and race-matched control individuals were recruited from a tertiary care dermatology clinic in New Orleans, Louisiana. Individuals with active infection, cancer, or other autoimmune disease were excluded. Additionally, those with use of systemic medication (systemic antibiotics, antiandrogen therapy, immunosuppressants, immunomodulators) within 1 month of sample collection, or biologics within 6 months, were excluded.

Demographic information and blood samples were collected. Twenty-five cytokines were quantified in duplicate using a multiplex assay (Millipore Human TH17 Magnetic Bead Panel [Millipore, Burlington, MA] and Luminex xMAP technology [Luminex, Austin, TX]).

Demographics were analyzed using a 2-tailed *t* test for continuous variables and chi-square and Fisher's exact tests for noncontinuous variables. Mann-Whitney and Kruskal-Wallis tests were used when evaluating cytokine levels. For data below the detection limit, a value of 0 was used. A *P* value of  $\leq .05$  was considered significant.



**Fig 1.** Cytokine levels in African American patients versus those of other races. A comparison of serum concentrations of TNF- $\alpha$ , IL-22, IL-23, IL-17F, IL-27, and IL-10 in African American patients (n = 16) and those of other races (n = 11) with hidradenitis suppurativa. *IL*, Interleukin; *TNF*, tumor necrosis factor.